CLINICAL TRIALS AT
Seattle Cancer
Care Alliance
SCCA has over 200 clinical trials open for patients and intends to lead the world in translating scientific discovery into the prevention, diagnosis, treatment and cure of cancer.
Recently Opened Trials
VTX-2337 for Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (7406)
Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN)
Ampligen w/Vaccine Therapy for Stage II-IV HER2-Positive Breast Cancer (7425)
Phase I-II Study of HER2 Vaccination with poly(I) Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients
PEGPH20 for Stage IV Previously Untreated Pancreatic Cancer (2542.00)
A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine (Gemzar) Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer
Radiation Therapy + Cisplatin & Etoposide for Inoperable NSCLC (7506)
A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer
Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Pazopanib in Combination w/ Radioactive 131I (7529)
A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Autologous T Cells, Recombinant IFN Gamma, Cyclophosphamide and Aldesleukin for Metastatic Soft Tissue Sarcoma (2537)
A Phase I Study To Determine the Safety of Autologous NY-ESO-1 Specific CD8+ T Cells For Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma in the Context of A Novel Regimen Combining Low Dose Weekly IFN-gamma With Cyclophosphamide Conditioning and Post-Infusional Low Dose IL-2
Paclitaxel With or Without Pazopanib in Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (GOG 186-J)
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Join Us On